Overview
- Sanna, E. et al. (2003) J. Neurosci. 23, 11711.
- Möhler, H. et al. (1980) Proc. Natl. Acad. Sci. U. S. A. 77, 1666.
- Alomone Labs Lorazepam inhibits specific binding of Flunitrazepam to rat brain GABA(A) receptors.Percent inhibition of specific binding of 1 nM [3H]Flunitrazepam to membranes from whole rat brain (except cerebellum) was plotted against increasing concentrations of Lorazepam (#L-230). Full inhibition is achieved at over 1 µM.
- Spyker, D.A. et al. (2015) Pharmacol. Res. Perspect. 3, 6.
- Pomara, N. et al. (2015) Prog. Neuropsychopharmacol. Biol. Psychiatry. 56, 35.
- Nohria, V. and Giller, E. (2007) Neurotherapeutics 4, 102.
- Möhler, H. et al. (1980) Proc. Natl. Acad. Sci. U. S. A. 77, 1666.
Lorazepam (also called Ativan), acts as a positive allosteric modulator of GABA(A) receptors at the benzodiazepine site. It is used to treat anxiety disorders and is a sedative and anticonvulsant drug. Lorazepam is one of the most common benzodiazepines used to control acute agitation and is commonly administered with antipsychotics1.
Lorazepam has a better safety profile compared to other benzodiazepines2. The drug has IC50 values of 4.8 nM in rat cerebral cortex4.
GABA(A) receptors are members of the Cys-loop superfamily of ligand-gated ion channels. They mediate GABA action, a major inhibitory neurotransmitter, through the central nervous system. The GABAA receptor is considered to be a major target of antiseizure drugs3.
Lorazepam (#L-230) is a highly pure, synthetic, and biologically active compound.